BRIEF-Apogee Therapeutics - Enters Il-31R License Agreement With Paragon On June 17, 2026 - SEC Filing

Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.

APGE

0.00

June 22 (Reuters) - Apogee Therapeutics Inc APGE.O:

  • APOGEE THERAPEUTICS - ENTERS IL-31R LICENSE AGREEMENT WITH PARAGON ON JUNE 17, 2026 - SEC FILING

  • APOGEE THERAPEUTICS - TO PAY PARAGON UP TO $23.25 MILLION FOR MILESTONES UNDER IL-31R LICENSE AGREEMENT - SEC FILING

  • APOGEE THERAPEUTICS - ENTERS ANTIBODY DISCOVERY AGREEMENT WITH PARAGON THERAPEUTICS ON JUNE 17, 2026 - SEC FILING

  • APOGEE THERAPEUTICS - TO PAY PARAGON $1.3 MILLION-$2 MILLION FOR CMC ACTIVITIES - SEC FILING

Source text: [ID:n0001140361-26-025841]

Further company coverage: APGE.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.